[1. Jespersen CG, Norgaard M, Borre M. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study. Eur Urol 2014; 65: 704-9.10.1016/j.eururo.2013.02.00223433805]Search in Google Scholar
[2. Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 2005; 90: 6410-17.10.1210/jc.2005-018316189261]Search in Google Scholar
[3. Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006; 24: 4448-56.10.1200/JCO.2006.06.249716983113]Search in Google Scholar
[4. Templeton AJ, Vera-Badillo FE, Wang L, Attalla M, Gouveia P, Leibowitz-Amit R, et al. Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. Ann Oncol 2013; 24: 2972-77.10.1093/annonc/mdt39724126362]Search in Google Scholar
[5. Piccirillo JF, Vlahiotis A, Barrett LB, Flood KL, Spitznagel EL, Steyerberg EW. The changing prevalence of comorbidity across the age spectrum. Crit Rev Oncol Hematol 2008; 67: 124-32.10.1016/j.critrevonc.2008.01.013253665018375141]Search in Google Scholar
[6. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12.10.1056/NEJMoa04072015470213]Search in Google Scholar
[7. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-20.10.1056/NEJMoa04131815470214]Search in Google Scholar
[8. Horgan AM, Seruga B, Pond GR, Alibhai SM, Amir E, De Wit R, et al. Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial. J Geriatr Oncol 2014; 5: 119-26.10.1016/j.jgo.2013.12.001435231524495703]Search in Google Scholar
[9. Chao HH, Mayer T, Concato J, Rose MG, Uchio E, Kelly WK. Prostate cancer, comorbidity, and participation in randomized controlled trials of therapy. J Investig Med 2010; 58: 566-8.10.2310/JIM.0b013e3181cf9002]Search in Google Scholar
[10. Harris V, Lloyd K, Forsey S, Rogers P, Roche M, Parker C. A population-based study of prostate cancer chemotherapy. Clin Oncol (R Coll Radiol) 2011; 23: 706-8.10.1016/j.clon.2011.04.01421602036]Search in Google Scholar
[11. Lund L, Borre M, Jacobsen J, Sorenson HT, Norgaard M. Impact of comorbidity on survival of Danish prostate cancer patients, 1995-2006: a population-based cohort study. Urology 2008; 72: 1258-62.10.1016/j.urology.2007.12.018]Search in Google Scholar
[12. Albertsen PC, Moore DF, Shih W, Lin Y, Lu-Yao GL. Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol 2011; 29: 1335-41.10.1200/JCO.2010.31.2330]Search in Google Scholar
[13. Daskivich TJ, Chamie K, Kwan L, Labo J, Dash A, Greenfield S, et al. Comorbidity and competing risks for mortality in men with prostate cancer. Cancer 2011; 117: 4642-50.10.1002/cncr.26104]Search in Google Scholar
[14. Halabi S, Kelly WK, George DJ, Morris MJ, Kaplan EB, Small EJ. Comorbidities predict overall survival (OS) in men with metastatic castrate-resistant prostate cancer. [Abstract]. J Clin Oncol 2011; 29(Suppl 7): abstr 189.10.1200/jco.2011.29.7_suppl.189]Search in Google Scholar
[15. Goyal J, Pond GR, Galsky MD, Hendricks R, Small A, Tsao CK, et al. Association of the Charlson comorbidity index and hypertension with survival in men with metastatic castration-resistant prostate cancer. Urol Oncol 2014; 32: 36. e27-34.10.1016/j.urolonc.2013.02.015]Search in Google Scholar
[16. Alibhai SM, Leach M, Tomlinson GA, Krahn MD, Fleshner NE, Naglie G. Is there an optimal comorbidity index for prostate cancer? Cancer 2008; 112: 1043-50.]Search in Google Scholar
[17. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994; 47: 1245-51.10.1016/0895-4356(94)90129-5]Search in Google Scholar
[18. Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 2004; 291: 2441-7.10.1001/jama.291.20.244115161894]Search in Google Scholar
[19. Italiano A, Ortholan C, Oudard S, Pouessel D, Gravis G, Beuzeboc P, et al. Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer. Eur Urol 2009; 55: 1368-75.10.1016/j.eururo.2008.07.07818706755]Search in Google Scholar
[20. Vickers MM, Powell ED, Asmis TR, Jonker DJ, Hilton JF, O’Callaghan CJ, et al. Comorbidity, age and overall survival in patients with advanced pancreatic cancer - results from NCIC CTG PA.3: a phase III trial of gemcitabine plus erlotinib or placebo. Eur J Cancer 2012; 48: 1434-42.10.1016/j.ejca.2011.10.03522119354]Search in Google Scholar
[21. Asmis TR, Powell E, Karapetis CS, Jonker DJ, Tu D, Jeffery M, et al. Comorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC)--results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care. Ann Oncol 2011; 22: 118-26.10.1093/annonc/mdq30920603436]Search in Google Scholar
[22. Droz JP, Aapro M, Balducci L, Boyle H, Van den Broeck T, Cathcart P, et al. Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncol 2014; 15: e404-14.10.1016/S1470-2045(14)70018-X]Search in Google Scholar
[23. Donze J, Lipsitz S, Bates DW, Schnipper JL. Causes and patterns of readmissions in patients with common comorbidities: retrospective cohort study. BMJ 2013; 347: f7171.10.1136/bmj.f7171389870224342737]Search in Google Scholar
[24. Hernandez C, Jansa M, Vidal M, Nunez M, Bertran MJ, Garcia-Avmerich J, et al. The burden of chronic disorders on hospital admissions prompts the need for new modalities of care: a cross-sectional analysis in a tertiary hospital. QJM 2009; 102: 193-202.10.1093/qjmed/hcn17219147657]Search in Google Scholar
[25. Zauderer MG, Sima CS, Korc-Grodzicki B, Kris MG, Krug LM. Toxicity of initial chemotherapy in older patients with lung cancers. J Geriatr Oncol 2013; 4: 64-70.10.1016/j.jgo.2012.09.003360175423525607]Search in Google Scholar
[26. Aparicio T, Jouve JL, Teillet L, Gargot D, Subtil F, Le Bruna-Ly V, et al. Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patients. J Clin Oncol 2013; 31: 1464-70.10.1200/JCO.2012.42.989423460711]Search in Google Scholar
[27. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014; 371: 424-33.10.1056/NEJMoa1405095441893124881730]Search in Google Scholar
[28. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368: 138-48.10.1056/NEJMoa1209096368357023228172]Search in Google Scholar
[29. Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369: 213-23.10.1056/NEJMoa121375523863050]Search in Google Scholar